StockWatch
·

Research Reports

02 Nov 2026
ASTERDMAster DM Healthcare Ltd

Merger Momentum: Tracking the Margin Expansion in a Consolidated Aster DM

healthcare · merger consolidation · EBITDA margin

Result previewQ2 FY273 minPharma & Healthcare
GLENMARKGLENMARK PHARMACEUTICALS LTD.

US growth and product momentum to sustain Q2 pull-forward

GLENMARK · Q2 FY27 · pharma

Result previewQ2 FY273 minPharma & Healthcare
ZYDUSLIFEZydus Lifesciences Ltd

Margin recovery and US momentum in focus as Zydus targets 24% EBITDA

margin recovery · US generics · India formulations

Result previewQ2 FY273 minPharma & Healthcare
APOLLOHOSPAPOLLO HOSPITALS ENTERPRISE LTD.

Sustaining momentum into the second half — execution on 20% guidance

healthcare · earnings · guidance

Result previewQ2 FY273 minPharma & Healthcare
DIVISLABDIVI'S LABORATORIES LTD.

Custom Synthesis Engine Hits Stride—Can the Margin Lift Sustain?

custom synthesis · margin expansion · EBITDA

Result previewQ2 FY273 minPharma & Healthcare
01 Nov 2026
SAIPARENTSai Parenterals Ltd

Sai Parenterals Q2 FY27: PAT +66% YoY, NPM halves to 5.3% as M&A triples revenue

pharma cdmo · margin dilution · acquisition driven growth

ResultsQ2 FY273 minPharma & Healthcare
31 Oct 2026
SGRLShree Ganesh Remedies Ltd

SGR Q2FY27: PAT -67% YoY to ₹1.63 Cr, OPM halves despite Block-7-led revenue rebound

speciality chemicals · api intermediates · margin compression

ResultsQ2 FY273 minPharma & Healthcare
APLLTDALEMBIC PHARMACEUTICALS LTD.

Alembic gets final USFDA approval for Venetoclax; first-to-file status may bring 180 days of exclusivity

USFDA · ANDA approval · Venetoclax

Research4 minPharma & Healthcare
30 Oct 2026
MANKINDMankind Pharma Ltd

Margin Beat Masks Consumer Healthcare Turnaround Risk

EBITDA margin · Consumer Healthcare · tax headwind

Result verdictFollow-upQ2 FY276 minPharma & Healthcare
MANKINDMankind Pharma Ltd

Margin beat masks consumer healthcare turnaround pending

EBITDA upside · consumer weakness · chronic expansion

TranscriptDeep diveQ2 FY276 minPharma & Healthcare
SUNPHARMASUN PHARMACEUTICAL INDUSTRIES LTD.

Sun Pharma Q2FY27: PAT -36% YoY on one-offs, adjusted PAT flat vs 12% revenue growth

pharma · exceptional items · organon acquisition

ResultsQ2 FY273 minPharma & Healthcare
TTKHLTCARETTK HEALTHCARE LTD.-$

TTK Healthcare Q2 FY27: PAT soars on brand-sale gain, core profit down ~8% YoY

fmcg · brand divestiture · exceptional gain

ResultsQ2 FY273 minPharma & Healthcare
AJANTPHARMAJANTA PHARMA LTD.

Ajanta Pharma Q2FY27: consolidated PAT +49% YoY as margins beat guidance

pharmaceuticals · margin expansion · us generics growth

ResultsQ2 FY273 minPharma & Healthcare
AUROPHARMAAUROBINDO PHARMA LTD.

US momentum and margin hold—the setup for Q2

US generics · EBITDA margin · biosimilars

Result previewQ2 FY273 minPharma & Healthcare
29 Oct 2026
INDOCOINDOCO REMEDIES LTD.

Revenue milestone, margin collapse—execution risk rises

margin compression · freight impact · regulated markets

Result verdictFollow-upQ2 FY276 minPharma & Healthcare
INDOCOINDOCO REMEDIES LTD.

500 Cr crossed, margins crushed; freight headwind masking underlying growth

margin compression · emerging markets strength · freight impact

TranscriptDeep diveQ2 FY276 minPharma & Healthcare
THYROCAREThyrocare Technologies Ltd

Consolidated PAT dives 68% YoY on ₹45 Cr NHL writedown; revenue +25%, adjusted PAT +26%

diagnostics · pathology · exceptional item

ResultsQ2 FY273 minPharma & Healthcare
LAURUSLABSLaurus Labs Ltd

Laurus Labs Q2 FY27: consolidated PAT up 124% YoY to ₹436 Cr as OPM expands to 34%

cdmo · margin expansion · operating leverage

ResultsQ2 FY273 minPharma & Healthcare
INDSWFTLABIND-SWIFT LABORATORIES LTD.

Ind-Swift Labs: consol PAT up 3.3x YoY to ₹34.2 Cr as EBITDA margin hits 18% floor

pharmaceuticals · cdmo exports · margin expansion

ResultsQ2 FY273 minPharma & Healthcare
SENORESSenores Pharmaceuticals Ltd

Senores Q2 FY27: PAT +22% YoY to ₹37 Cr, margins expand but growth trails 50-60% guide

generic pharmaceuticals · anda pipeline · margin expansion

ResultsQ2 FY273 minPharma & Healthcare
TORNTPHARMTORRENT PHARMACEUTICALS LTD.

Revenue surge masks PAT decline; integration ongoing, base business resilient

JB integration · cost synergies · PAT erosion

TranscriptDeep diveQ2 FY276 minPharma & Healthcare
LALPATHLABDr. Lal PathLabs Ltd

Can Dr. Lal PathLabs sustain Q1's 19% growth as it scales acquisitions?

diagnostics · revenue growth · margin expansion

Result previewQ2 FY273 minPharma & Healthcare
KIMSKrishna Institute of Medical Sciences Ltd

New Units Ramping — Can Momentum Offset Margin Pressure?

healthcare · hospital expansion · margin pressure

Result previewQ2 FY273 minPharma & Healthcare
WOCKPHARMAWOCKHARDT LTD.

Turnaround Holds — Profitability Momentum into Q2 on Watch

pharma · turnaround · Q2 FY27

Result previewQ2 FY273 minPharma & Healthcare
28 Oct 2026
SANOFICONRSanofi Consumer Healthcare India Ltd

Sanofi Consumer Healthcare: Q2 FY27 PAT +22% YoY, margins expand on domestic growth

consumer healthcare · pharma · margin expansion

ResultsQ2 FY273 minPharma & Healthcare
FDCFDC LTD.

FDC pairs a ₹120 Cr buyback at ₹500 — 41% above the pre-announcement close — with a 73% jump in Q2 profit

FDC · buyback · tender offer

Research4 minPharma & Healthcare
PFIZERPFIZER LTD.

Mid-cycle momentum on track, but Minipress discontinuation casts shadow

pharma earnings · revenue growth · minipress discontinuation

Result previewQ2 FY273 minPharma & Healthcare
NEULANDLABNEULAND LABORATORIES LTD.

CDMO Expansion Test: Can Neuland Hold Margins in a Growth Year?

CDMO · peptide-expansion · FDA-approval

Result previewQ2 FY273 minPharma & Healthcare
EMCUREEmcure Pharmaceuticals Ltd

Emcure expects to sustain export momentum—watch for margin trajectory amid higher international mix

export growth · margin trajectory · Gennova integration

Result previewQ2 FY273 minPharma & Healthcare
NHNarayana Hrudayalaya Ltd

Sustaining Q1's momentum: execution and new-bed ramp in focus

Result previewQ2 FY273 minPharma & Healthcare